Details
| Titel in Übersetzung | Suitability and Usability of Claims Data for Review of Guidelines for the Treatment of Chronic Heart Failure |
|---|---|
| Originalsprache | Deutsch |
| Seiten (von - bis) | e135-e144 |
| Fachzeitschrift | Gesundheitswesen, Supplement |
| Jahrgang | 78 |
| Ausgabenummer | S 01 |
| Frühes Online-Datum | 7 Apr. 2016 |
| Publikationsstatus | Veröffentlicht - Sept. 2016 |
Abstract
Background: Guidelines have special importance in medicine, however, it is questionable to what extent these recommendations are applied in daily care, and under which conditions claims data can be used for verification of guideline adherence. Method: Advantages and limitations of claims data for verification of guidelines compliance in the therapeutic area as well as the guidelines themselves were analysed and critically assessed. To substantiate these results, claims data of a major German health insurance fund (Techniker Krankenkasse) were analysed. Results: 104 236 patients were identified. With certain limitations, claims data are useful for verifying guideline adherence; it could be shown that in pharmacotherapy the beta-adrenergic receptor blocker was used to the highest extent (70.5%). In contrast, only 56.4% of patients were treated with pure ACE inhibitors and ACE combined preparation. Conclusion: In order to validate guideline adherence by means of claims data analyses, a number of conditions relating to the database, the therapeutic area and the guidelines themselves have to be considered. Guideline recommendations, which, for example, are based on clinical data, cannot be reviewed by using claims data. Despite these limitations, claims data provide a suitable tool for reviewing selected guideline recommendations. They show that the current use of pharmacotherapy as well as clinical and diagnostic interventions might be increased in accordance with the guideline recommendations.
Schlagwörter
- cardiology, claims data, guideline adherence, guidelines, heart failure
ASJC Scopus Sachgebiete
- Medizin (insg.)
- Öffentliche Gesundheit, Umwelt- und Arbeitsmedizin
Ziele für nachhaltige Entwicklung
Zitieren
- Standard
- Harvard
- Apa
- Vancouver
- BibTex
- RIS
in: Gesundheitswesen, Supplement, Jahrgang 78, Nr. S 01, 09.2016, S. e135-e144.
Publikation: Beitrag in Fachzeitschrift › Artikel › Forschung › Peer-Review
}
TY - JOUR
T1 - Eignung und Anwendung von GKV-Routinedaten zur Überprüfung von Versorgungsleitlinien am Beispiel der Indikation Linksherzinsuffizienz
AU - Neubauer, S.
AU - Zeidler, J.
AU - Schilling, T.
AU - Engel, S.
AU - Linder, R.
AU - Verheyen, F.
AU - Haverich, A.
AU - Von Der Schulenburg, J. M.G.
PY - 2016/9
Y1 - 2016/9
N2 - Background: Guidelines have special importance in medicine, however, it is questionable to what extent these recommendations are applied in daily care, and under which conditions claims data can be used for verification of guideline adherence. Method: Advantages and limitations of claims data for verification of guidelines compliance in the therapeutic area as well as the guidelines themselves were analysed and critically assessed. To substantiate these results, claims data of a major German health insurance fund (Techniker Krankenkasse) were analysed. Results: 104 236 patients were identified. With certain limitations, claims data are useful for verifying guideline adherence; it could be shown that in pharmacotherapy the beta-adrenergic receptor blocker was used to the highest extent (70.5%). In contrast, only 56.4% of patients were treated with pure ACE inhibitors and ACE combined preparation. Conclusion: In order to validate guideline adherence by means of claims data analyses, a number of conditions relating to the database, the therapeutic area and the guidelines themselves have to be considered. Guideline recommendations, which, for example, are based on clinical data, cannot be reviewed by using claims data. Despite these limitations, claims data provide a suitable tool for reviewing selected guideline recommendations. They show that the current use of pharmacotherapy as well as clinical and diagnostic interventions might be increased in accordance with the guideline recommendations.
AB - Background: Guidelines have special importance in medicine, however, it is questionable to what extent these recommendations are applied in daily care, and under which conditions claims data can be used for verification of guideline adherence. Method: Advantages and limitations of claims data for verification of guidelines compliance in the therapeutic area as well as the guidelines themselves were analysed and critically assessed. To substantiate these results, claims data of a major German health insurance fund (Techniker Krankenkasse) were analysed. Results: 104 236 patients were identified. With certain limitations, claims data are useful for verifying guideline adherence; it could be shown that in pharmacotherapy the beta-adrenergic receptor blocker was used to the highest extent (70.5%). In contrast, only 56.4% of patients were treated with pure ACE inhibitors and ACE combined preparation. Conclusion: In order to validate guideline adherence by means of claims data analyses, a number of conditions relating to the database, the therapeutic area and the guidelines themselves have to be considered. Guideline recommendations, which, for example, are based on clinical data, cannot be reviewed by using claims data. Despite these limitations, claims data provide a suitable tool for reviewing selected guideline recommendations. They show that the current use of pharmacotherapy as well as clinical and diagnostic interventions might be increased in accordance with the guideline recommendations.
KW - cardiology
KW - claims data
KW - guideline adherence
KW - guidelines
KW - heart failure
UR - http://www.scopus.com/inward/record.url?scp=84988599466&partnerID=8YFLogxK
U2 - 10.1055/s-0042-100727
DO - 10.1055/s-0042-100727
M3 - Artikel
AN - SCOPUS:84988599466
VL - 78
SP - e135-e144
JO - Gesundheitswesen, Supplement
JF - Gesundheitswesen, Supplement
SN - 0949-7013
IS - S 01
ER -